Scienture Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its liquid formulation of losartan, branded as ArbliTM (losartan potassium) Oral Suspension ...

Arbli is designed for patients who require or prefer an oral liquid formulation of losartan. According to Scienture, the oral suspension provides a convenient and safe option, removing the ...

Scienture shares originally traded higher on Tuesday but have since reversed and began trading lower after the company ...

Losartan (Cozaar) is a generic drug that is prescribed for certain conditions, including high blood pressure. Losartan comes as an oral tablet and belongs to the angiotensin II receptor blocker ...

Arbli TM is the first and only FDA approved ready-to-use oral liquid losartan in the U.S. market. Arbli TM is a novel proprietary formulation of losartan, a proven therapy for treating ...

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers ...

Read below for more. Scienture is advancing a liquid formulation of the popular blood pressure drug losartan, for which the FDA has a target action date of March 17. The asset, dubbed SCN-102, is ...

HOLDINGS has completed a draw on its Equity Line of Credit to support the commercial launch of Arbli Oral Suspension, while ...

Scienture (SCNX) announces the U.S. Food and Drug Administration, FDA, has approved SCN-102, one of the products being developed by Scienture, ...